10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

IARS2 Antibody (N-term)

Purified Rabbit Polyclonal Antibody (Pab)
Catalog # AP20876b

Product Information

Application	WB, E
Primary Accession	Q9NSE4
Reactivity	Human
Host	Rabbit
Clonality	Polyclonal
Isotype	Rabbit IgG
Clone Names	RB50228
Calculated MW	113792

Additional Information

Gene ID	55699
Other Names	Isoleucine--tRNA ligase, mitochondrial, Isoleucyl-tRNA synthetase, IleRS, IARS2
Target/Specificity	This IARS2 antibody is generated from a rabbit immunized with a KLH conjugated synthetic peptide between 51-82 amino acids from the N-terminal region of human IARS2.
Dilution	WB~~1:1000 E~~Use at an assay dependent concentration.
Format	Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.
Storage	Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Precautions	IARS2 Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures.


Protein Information

Name	IARS2 (HGNC:29685)
Function	Aminoacyl-tRNA synthetase that catalyzes the specific attachment of isoleucine to its cognate tRNA (tRNA(Ile)).
Cellular Location	Mitochondrion matrix.

References

Shan Y.X.,et al.Submitted (APR-2003) to the EMBL/GenBank/DDBJ databases.
Gregory S.G.,et al.Nature 441:315-321(2006).
Mural R.J.,et al.Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
Shiba K.,et al.Submitted (FEB-1994) to the EMBL/GenBank/DDBJ databases.
Ota T.,et al.Nat. Genet. 36:40-45(2004).

Images



Western blot analysis of lysate from A431 cell line, using IARS2 Antibody (N-term)(Cat. #AP20876b). AP20876b was diluted at 1:1000. A goat anti-rabbit IgG H&L(HRP) at 1:10000 dilution was used as the secondary antibody. Lysate at 20ug.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.